MDM2 and neoplasm: The proposal has already shown promising preliminary results in some preclinical studies, such as the combination of MDM2 inhibitors with AURKA inhibitors (senescence inducers), which not only induced melanoma cell death but also promoted the expression of numerous immune factors, thereby enhancing the anti-tumor immune response (33).